thiamine has been researched along with Cognitive Dysfunction in 11 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reduced thiamine is one of the predictors for early cognitive impairment in patients with acute cerebral infarction." | 7.96 | Reduced thiamine is a predictor for cognitive impairment of cerebral infarction. ( Cheng, H; Feng, L; He, J; He, W; Huang, G; Lin, S; Liu, Y; Yuan, C, 2020) |
| "Evidence suggests that improving brain inflammation can inhibit the epileptogenesis process and help the emergence of new drugs for the treatment of epilepsy." | 5.72 | Thiamine alleviates cognitive impairment and epileptogenesis by relieving brain inflammation in PTZ-induced kindling rat model. ( Akkaya, R; Filiz, AK; Karabulut, S, 2022) |
| "Reduced thiamine is one of the predictors for early cognitive impairment in patients with acute cerebral infarction." | 3.96 | Reduced thiamine is a predictor for cognitive impairment of cerebral infarction. ( Cheng, H; Feng, L; He, J; He, W; Huang, G; Lin, S; Liu, Y; Yuan, C, 2020) |
| "Despite the absence of thiamine deficiency, whole blood thiamine was lower in patients with dementia and delirium compared to those without." | 3.91 | Blood Thiamine Level and Cognitive Function in Older Hospitalized Patients. ( Angersbach, B; Klimek, CN; Lueg, G; Pourhassan, M; Wirth, R, 2019) |
| "The primary clinical outcome was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)." | 2.94 | Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. ( Bettendorff, L; Chen, H; Chen, Z; Cirio, R; Flowers, SA; Fonzetti, P; Franchino-Elder, J; Gerber, LM; Gibson, GE; Grandville, T; Habeck, C; Hirsch, JA; Jordan, B; Luchsinger, JA; Schupf, N; Stern, Y; Xu, H, 2020) |
| "Evidence suggests that improving brain inflammation can inhibit the epileptogenesis process and help the emergence of new drugs for the treatment of epilepsy." | 1.72 | Thiamine alleviates cognitive impairment and epileptogenesis by relieving brain inflammation in PTZ-induced kindling rat model. ( Akkaya, R; Filiz, AK; Karabulut, S, 2022) |
| "Riboflavin and folate were significantly and independently associated with cognitive impairment in a dose-dependent manner: the odds ratio (95% confidence interval) comparing the highest with the lowest quartile was 0." | 1.56 | Association Between Dietary Intakes of B Vitamins in Midlife and Cognitive Impairment in Late-Life: The Singapore Chinese Health Study. ( Feng, L; Jiang, YW; Koh, WP; Pan, A; Pan, XF; Sheng, LT; Yuan, JM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 9 (81.82) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, Y | 1 |
| Chen, ZY | 1 |
| Ma, WJ | 1 |
| Wang, QZ | 1 |
| Liang, H | 1 |
| Ma, AG | 1 |
| Lu, R | 1 |
| Gu, LY | 1 |
| Zhang, W | 1 |
| Guo, Y | 1 |
| Zang, X | 1 |
| Zhou, Y | 1 |
| Yu, L | 1 |
| Pan, S | 1 |
| Pang, H | 1 |
| Liu, S | 1 |
| Xie, K | 1 |
| Li, P | 1 |
| Zeng, X | 1 |
| Lu, Y | 1 |
| Karabulut, S | 1 |
| Filiz, AK | 1 |
| Akkaya, R | 1 |
| Coulbault, L | 1 |
| Ritz, L | 1 |
| Vabret, F | 1 |
| Lannuzel, C | 1 |
| Boudehent, C | 1 |
| Nowoczyn, M | 1 |
| Beaunieux, H | 1 |
| Pitel, AL | 1 |
| Mainz-Perchalla, A | 1 |
| Håglin, L | 1 |
| Domellöf, M | 1 |
| Bäckman, L | 1 |
| Forsgren, L | 1 |
| Feng, L | 2 |
| He, W | 1 |
| Huang, G | 1 |
| Lin, S | 1 |
| Yuan, C | 1 |
| Cheng, H | 1 |
| He, J | 1 |
| Liu, Y | 1 |
| Gibson, GE | 1 |
| Luchsinger, JA | 1 |
| Cirio, R | 1 |
| Chen, H | 1 |
| Franchino-Elder, J | 1 |
| Hirsch, JA | 1 |
| Bettendorff, L | 1 |
| Chen, Z | 1 |
| Flowers, SA | 1 |
| Gerber, LM | 1 |
| Grandville, T | 1 |
| Schupf, N | 1 |
| Xu, H | 1 |
| Stern, Y | 1 |
| Habeck, C | 1 |
| Jordan, B | 1 |
| Fonzetti, P | 1 |
| Pourhassan, M | 1 |
| Angersbach, B | 1 |
| Lueg, G | 1 |
| Klimek, CN | 1 |
| Wirth, R | 1 |
| Sheng, LT | 1 |
| Jiang, YW | 1 |
| Pan, XF | 1 |
| Yuan, JM | 1 |
| Pan, A | 1 |
| Koh, WP | 1 |
| Rommer, PS | 1 |
| Fuchs, D | 1 |
| Leblhuber, F | 1 |
| Schroth, R | 1 |
| Greilberger, M | 1 |
| Tafeit, E | 1 |
| Greilberger, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benfotiamine in Alzheimer's Disease: A Pilot Study[NCT02292238] | Phase 2 | 71 participants (Actual) | Interventional | 2015-02-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials and is considered to be the gold standard for assessing antidementia treatments. The ADAS-Cog range from 0 to 70, where higher scores indicate greater cognitive dysfunction." (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 1.39 |
| Placebo | 3.26 |
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) is a caregiver-based Activities of Daily Living (ADL) scale composed of 23 items developed for use in dementia clinical studies. It was designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, as well as making judgments and decisions. The range for the total ADCS-ADL score is 0 to 78. Higher scores equate with higher functioning. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | -1.931 |
| Placebo | -3.16129 |
The AAL (Automatic Anatomical Labeling) atlas provides the taxonomy for 116 regions of interest, 90 of which capture non-cerebellar cortical regions. Signal averages from 9 cerebellar regions from each hemisphere were further averaged into one composite cerebellar region for each hemisphere, 'Cerebellum_L' and 'Cerebellum_R', which were comprised of the respective laterality averages of the regions: 'Cerebellum_Crus1 ' 'Cerebellum_Crus2 'Cerebellum_3' 'Cerebellum_4_5' 'Cerebellum_6' 'Cerebellum_7b' 'Cerebellum_8' 'Cerebellum_9' 'Cerebellum_10 '. Subsequently, these two composite regions are further combined with the bilateral paracentral lobules to provide one final composite for reference scaling. Concretely, the values from 'Cerebellum_L', 'Cerebellum_R', 'Paracentral_Lobule_L', and 'Paracentra_Lobule_R' were averaged. This final composite will serve as the denominator for the scaling operation of any ROI value prior to group-level analysis. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | ratio (Mean) |
|---|---|
| Benfotiamine | -0.02 |
| Placebo | -0.01 |
The SRT is a standard diagnostic tool in the assessment of verbal memory. The Buschke SRT immediate total scores are compared between treated (benfotiamine) and control (placebo) groups. The immediate total score is the sum of correct responses over the 6 learning trials with scores ranging from 0 to 72. A score of 0 means severe impairment in memory. A score of 72 means there is no impairment in memory. For the purpose of determining effect over several trials between groups, the fractional change from the baseline of each group is compared. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.86 |
| Placebo | -1.12 |
The CDR was developed primarily for use in persons with dementia of the Alzheimer type (the equivalent of probable Alzheimer's Disease) and can also be used to stage dementia in other illnesses as well. The scores for the multiple items are summarized in one score. The CDR examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.05 |
| Placebo | 0.22 |
The NPI assesses a wide range of behaviors encountered in dementia patients to provide a means of distinguishing frequency and severity of behavioral changes. Ten behavioral and two neuro-vegetative domains are evaluated through an interview with the caregiver. The total score ranges from 0 to 144. Higher scores suggest greater psychiatric impairment. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 6.69 |
| Placebo | 9.23 |
3 trials available for thiamine and Cognitive Dysfunction
| Article | Year |
|---|---|
Protocol for thiamine and folic acid in the treatment of cognitive impairment in maintenance haemodialysis patients: a prospective, randomised, placebo-controlled, double-blind, multicentre study.
Topics: China; Cognitive Dysfunction; Double-Blind Method; Folic Acid; Humans; Multicenter Studies as Topic; | 2021 |
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Apolipoprotein E4; Brain; Cognitive D | 2020 |
Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Topics: Age Factors; Aged; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Dietary Supplements; Discri | 2016 |
8 other studies available for thiamine and Cognitive Dysfunction
| Article | Year |
|---|---|
B Vitamins Supplementation Can Improve Cognitive Functions and May Relate to the Enhancement of Transketolase Activity in A Rat Model of Cognitive Impairment Associated with High-fat Diets.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Folic A | 2021 |
Thiamine alleviates cognitive impairment and epileptogenesis by relieving brain inflammation in PTZ-induced kindling rat model.
Topics: Animals; Cognitive Dysfunction; Cyclooxygenase 2; Encephalitis; Epilepsy; Kindling, Neurologic; Male | 2022 |
Thiamine and phosphate esters concentrations in whole blood and serum of patients with alcohol use disorder: a relation with cognitive deficits.
Topics: Adult; Alcoholism; Cognitive Dysfunction; Esters; Female; Humans; Male; Middle Aged; Neuropsychologi | 2021 |
Vitamin B1 Deficiency Should not be Forgotten.
Topics: Cognition; Cognitive Dysfunction; Critical Care; Humans; Thiamine; Thiamine Deficiency | 2020 |
Low plasma thiamine and phosphate in male patients with Parkinson's disease is associated with mild cognitive impairment.
Topics: Case-Control Studies; Cognitive Dysfunction; Female; Humans; Male; Parkinson Disease; Phosphates; Th | 2020 |
Reduced thiamine is a predictor for cognitive impairment of cerebral infarction.
Topics: Brain Ischemia; Cerebral Infarction; Cognitive Dysfunction; Humans; Stroke; Thiamine | 2020 |
Blood Thiamine Level and Cognitive Function in Older Hospitalized Patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Cross-Section | 2019 |
Association Between Dietary Intakes of B Vitamins in Midlife and Cognitive Impairment in Late-Life: The Singapore Chinese Health Study.
Topics: Aged; Cognitive Dysfunction; Diet Surveys; Dose-Response Relationship, Drug; Eating; Female; Folic A | 2020 |